An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis

Brain and Behavior

Volumn 5, Issue 9, 2015, Pages

  Garg, Neeta ^a   Smith, Thomas W ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Demyelination; Diagnosis; Etiology; Immunomodulator; Multiple sclerosis; Pathogenesis; Treatment

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GLATIRAMER; MITOXANTRONE; NATALIZUMAB;

ARTICLE; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; ELEVATED BLOOD PRESSURE; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; BRAIN; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; PATHOLOGY; PROCEDURES; SPINAL CORD;

BRAIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; SPINAL CORD;

EID: 84941942611     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.362     Document Type: Article

References (115)

1. Aichele, P., M. F. Bachmann, H. Hengartner, and R. M. Zinkernagel 1996. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol. Rev. 152:21-45.
2. Ascherio, A. 2013. Environmental factors in multiple sclerosis. Expert Rev. Neurother. 13:3-9.
3. Ascherio, A., and K. L. Munger 2007a. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61:288-299.
4. Ascherio, A., and K. L. Munger 2007b. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann. Neurol. 61:504-513.
5. Ascherio, A., K. L. Munger, and K. C. Simon 2010. Vitamin D and multiple sclerosis. Lancet Neurol. 9:599-612.
6. ® (teriflunomide) Prescibing information. 2014. Genzyme Corp. (Accessed July 23, 2014).
7. Awad, A., B. Hemmer, H. P. Hartung, B. Kieseier, J. L. Bennett, and O. Stuve 2010. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J. Neuroimmunol. 219:1-7.
8. Barcellos, L. F., J. R. Oksenberg, A. B. Begovich, E. R. Martin, S. Schmidt, E. Vittinghoff, et al. 2003. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72:710-716.
9. Barkhof, F., W. Bruck, C. J. De Groot, E. Bergers, S. Hulshof, J. Geurts, et al. 2003. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Neurol. 60:1073-1081.
10. Barnett, M. H., and J. W. Prineas 2004. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55:458-468.
11. Batoulis, H., K. Addicks, and S. Kuerten 2010. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Annals Anat. 192:179-193.
12. Berkovich, R. 2013. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 10:97-105.
13. Bloomgren, G., S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, A. Natarajan, et al. 2012. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366:1870-1880.
14. Bogdan, F. P., I. Pirko, F. C. Lucchinetti, 2013. Pathology of multiple sclerosis: Where do we stand?. Cont. Lifelong Learn. Neurol. 19:901-921.
15. Bruck, W., and C. Stadelmann 2005. The spectrum of multiple sclerosis: new lessons from pathology. Curr. Opin. Neurol. 18:221-224.
16. Bruck, W., P. Porada, S. Poser, P. Rieckmann, F. Hanefeld, H. A. Kretzschmar, et al. 1995. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann. Neurol. 38:788-796.
17. Calic, Z., C. Cappelen-Smith, S. J. Hodgkinson, A. McDougall, R. Cuganesan, and B. J. Brew 2015. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J. Clin. Neurosci. 22:598-600.
18. Case of PML reported in patient treated with Gilenya®. https://beta.mssociety.ca/research-news/article/case-of-pml-reported-in-patient-treated-with-gilenya, 2015.
19. Chiba, K., Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi, M. Ohtsuki, et al. 1998. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160:5037-5044.
20. Cifelli, A., M. Arridge, P. Jezzard, M. M. Esiri, J. Palace, and P. M. Matthews 2002. Thalamic neurodegeneration in multiple sclerosis. Ann. Neurol. 52:650-653.
21. Cohen, J. A., F. Barkhof, G. Comi, H. P. Hartung, B. O. Khatri, X. Montalban, et al. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362:402-415.
22. Compston, A., and A. Coles 2008. Multiple sclerosis. Lancet 372:1502-1517.
23. Confavreux, C., P. O'Connor, G. Comi, M. S. Freedman, A. E. Miller, T. P. Olsson, et al. 2014. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13:247-256.
24. Conradi, S., U. Malzahn, F. Schroter, F. Paul, S. Quill, E. Spruth, et al. 2011. Environmental factors in early childhood are associated with multiple sclerosis: a case-control study. BMC Neurol. 11:123.
25. Correale, J., M. C. Ysrraelit, and M. I. Gaitan 2009. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 132:1146-1160.
26. Damal, K., E. Stoker, and J. F. Foley 2013. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics 7:247-258.
27. Dhib-Jalbut, S. 2002. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58:S3-S9.
28. Ermis, U., J. Weis, and J. B. Schulz 2013. PML in a patient treated with fumaric acid. N. Engl. J. Med. 368:1657-1658.
29. Farez, M. F., M. P. Fiol, M. I. Gaitan, F. J. Quintana, and J. Correale 2015. Sodium intake is associated with increased disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 86:26-31.
30. FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate). http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm, 2014. (Accessed January 8, 2015).
31. Filippi, M., M. A. Horsfield, S. P. Morrissey, D. G. MacManus, P. Rudge, W. I. McDonald, et al. 1994. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635-641.
32. Filippini, G., C. Del Giovane, L. Vacchi, R. D'Amico, C. Di Pietrantonj, D. Beecher, et al. 2013. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst. Rev. 6:CD008933.
33. Fox, E. J. 2006. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther. 28:461-474.
34. Fox, R. J., D. H. Miller, J. T. Phillips, M. Hutchinson, E. Havrdova, M. Kita, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367:1087-1097.
35. Fox, R. J., M. Kita, S. L. Cohan, L. J. Henson, J. Zambrano, R. H. Scannevin, et al. 2014. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr. Med. Res. Opin. 30:251-262.
36. Fragoso, Y. D. 2014. Modifiable environmental factors in multiple sclerosis. Arq. Neuropsiquiatr. 72:889-894.
37. Frischer, J. M., S. Bramow, A. Dal-Bianco, C. F. Lucchinetti, H. Rauschka, M. Schmidbauer, et al. 2009. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-1189.
38. Frohman, E. M., M. K. Racke, and C. S. Raine 2006. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354:942-955.
39. Fujinami, R. S., and M. B. Oldstone 1985. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043-1045.
40. Geurts, J. J., and F. Barkhof 2008. Grey matter pathology in multiple sclerosis. Lancet Neurol. 7:841-851.
41. Gold, R., and J. S. Wolinsky 2011. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol. Scand. 124:75-84.
42. Gold, R., C. Linington, and H. Lassmann 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971.
43. Gold, R., L. Kappos, D. L. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367:1098-1107.
44. Gran, B., B. Hemmer, M. Vergelli, H. F. McFarland, and R. Martin 1999. Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann. Neurol. 45:559-567.
45. Gran, B., L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, et al. 2000. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55:1704-1714.
46. Hafler, D. A., J. M. Slavik, D. E. Anderson, K. C. O'Connor, P. De Jager, and C. Baecher-Allan 2005. Multiple sclerosis. Immunol. Rev. 204:208-231.
47. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, et al. 2007. Risk alleles for multiple sclerosis identified by a genome wide study. N. Engl. J. Med. 357:851-862.
48. Hauser, S. L., A. K. Bhan, F. Gilles, M. Kemp, C. Kerr, and H. L. Weiner 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19:578-587.
49. Hemmer, B., J. J. Archelos, and H. P. Hartung 2002. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3:291-301.
50. Howell, O. W., C. A. Reeves, R. Nicholas, D. Carassiti, B. Radotra, S. M. Gentleman, et al. 2011. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134:2755-2771.
51. Ingle, G. T., J. Sastre-Garriga, D. H. Miller, and A. J. Thompson 2005. Is inflammation important in early PPMS? a longitudinal MRI study. J. Neurol. Neurosurg. Psychiatry 76:1255-1258.
52. Inglese, M. 2006. Multiple sclerosis: new insights and trends. AJNR Am. J. Neuroradiol. 27:954-957.
53. Kantarci, O. H. 2008. Genetics and natural history of multiple sclerosis. Semin. Neurol. 28:7-16.
54. Kappos, L., B. Weinshenker, C. Pozzilli, A. J. Thompson, F. Dahlke, K. Beckmann, et al. 2004. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63:1779-1787.
55. Kappos, L., E. W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, et al. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362:387-401.
56. Karussis, D. 2014. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J. Autoimmun. 48-49:134-142.
57. Kister, I., E. Chamot, A. R. Salter, G. R. Cutter, T. E. Bacon, and J. Herbert 2013. Disability in multiple sclerosis: a reference for patients and clinicians. Neurology 80:1018-1024.
58. Kleinewietfeld, M., A. Manzel, J. Titze, H. Kvakan, N. Yosef, R. A. Linker, et al. 2013. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496:518-522.
59. La Mantia, L., L. M. Munari, and R. Lovati 2010. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev. CD004678.
60. Lindsey, J. W., K. Haden-Pinneri, N. B. Memon, and L. M. Buja 2012. Sudden unexpected death on fingolimod. Mult. Scler. 18:1507-1508.
61. Link, H., and Y. M. Huang 2006. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. 180:17-28.
62. Linker, R. A., D. H. Lee, S. Ryan, A. M. van Dam, R. Conrad, P. Bista, et al. 2011. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678-692.
63. Lublin, F. D., and S. C. Reingold 1996. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911.
64. Lublin, F. D., S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sørensen, A. J. Thompson et al. 2014. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278-286.
65. Lucchinetti, C., W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707-717.
66. Lucchinetti, C. F., R. H. Gavrilova, I. Metz, J. E. Parisi, B. W. Scheithauer, S. Weigand, et al. 2008. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759-1775.
67. Lucchinetti, C. F., B. F. Popescu, R. F. Bunyan, N. M. Moll, S. F. Roemer, H. Lassmann, et al. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365:2188-2197.
68. Mayr, W. T., S. J. Pittock, R. L. McClelland, N. W. Jorgensen, J. H. Noseworthy, and M. Rodriguez 2003. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 61:1373-1377.
69. Miller, D. H., and S. M. Leary 2007. Primary-progressive multiple sclerosis. Lancet Neurol. 6:903-912.
70. Miller, S. D., C. L. Vanderlugt, W. S. Begolka, W. Pao, R. L. Yauch, K. L. Neville, et al. 1997. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3:1133-1136.
71. Miller, D. H., O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P. A. Rice, M. A. Libonati, et al. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15-23.
72. Miller, D., F. Barkhof, X. Montalban, A. Thompson, and M. Filippi 2005. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 4:281-288.
73. Montalban, X., M. Tintore, J. Swanton, F. Barkhof, F. Fazekas, M. Filippi, et al. 2010. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74:427-434.
74. Munger, K. L., S. M. Zhang, E. O'Reilly, M. A. Hernán, M. J. Olek, W. C. Willett, et al. 2004. Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60-65.
75. Munger, K. L., L. I. Levin, B. W. Hollis, N. S. Howard, and A. Ascherio 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832-2838.
76. Naismith, R. T., L. Piccio, J. A. Lyons, J. Lauber, N. T. Tutlam, B. J. Parks, et al. 2010. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74:1860-1867.
77. O'Connor, K. C., A. Bar-Or, and D. A. Hafler 2001. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol. 21:81-92.
78. O'Connor, P., J. S. Wolinsky, C. Confavreux, G. Comi, L. Kappos, T. P. Olsson, et al. 2011. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365:1293-1303.
79. Oh, J., and P. W. O'Connor 2013. An update of teriflunomide for treatment of multiple sclerosis. Ther. Clin. Risk Manag. 9:177-190.
80. van Oosten, B. W., J. Killestein, F. Barkhof, C. H. Polman, and M. P. Wattjes 2013. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N. Engl. J. Med. 368:1658-1659.
81. Orton, S. M., B. M. Herrera, I. M. Yee, W. Valdar, S. V. Ramagopalan, A. D. Sadovnick, et al. 2006. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5:932-936.
82. Pelletier, D., and D. A. Hafler 2012. Fingolimod for multiple sclerosis. N. Engl. J. Med. 366:339-347.
83. Polman, C. H., P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899-910.
84. Polman, C. H., S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen, M. Filippi, et al. 2011. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69:292-302.
85. Popescu, B. F., and C. F. Lucchinetti 2012. Pathology of demyelinating diseases. Annu. Rev. Pathol. 7:185-217.
86. Prineas, J. W., E. E. Kwon, E. S. Cho, L. R. Sharer, M. H. Barnett, E. L. Oleszak, et al. 2001. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50:646-657.
87. Ransohoff, R. M. 2007. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356:2622-2629.
88. Rudick, R. A., J. A. Cohen, B. Weinstock-Guttman, R. P. Kinkel, and R. M. Ransohoff 1997. Management of multiple sclerosis. N. Engl. J. Med. 337:1604-1611.
89. Ruggieri, M., C. Avolio, P. Livrea, and M. Trojano 2007. Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev. 13:178-191.
90. Samson, K. 2013. PML in suspected MS patient taking Fingolimod Raises FDA concerns. Neurology Today 13:37.
91. Sawcer, S., G. Hellenthal, M. Pirinen, C. C. Spencer, N. A. Patsopoulos, L. Moutsianas, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219.
92. Selter, C. R., and B. Hemmer 2013. Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immuno. Targets Therapy 2:21-30.
93. Simpson, S. Jr, L. Blizzard, P. Otahal, I. Van der Mei, and B. Taylor 2011. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82:1132-1141.
94. Sobel, R., and W. Moore 2008. Demyelinating diseases. Greenfield's neuropathology, London, UK: Oxford Univ. Press 2:1513-1608.
95. Sotgiu, S., M. Pugliatti, A. Sotgiu, A. Sanna, and G. Rosati 2003. Does the "hygiene hypothesis" provide an explanation for the high prevalence of multiple sclerosis in Sardinia? Autoimmunity 36:257-260.
96. Stadelmann, C., S. Ludwin, T. Tabira, A. Guseo, C. F. Lucchinetti, L. Leel-Ossy, et al. 2005. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 128:979-987.
97. Swanton, J. K., K. Fernando, C. M. Dalton, K. A. Miszkiel, A. J. Thompson, G. T. Plant, et al. 2006. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry 77:830-833.
98. Swanton, J. K., A. Rovira, M. Tintore, D. R. Altman, F. Barkhof, M. Filippi, et al. 2007. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 6:677-686.
99. Sweetser, M. T., K. T. Dawson, and C. Bozic 2013. Case reports of PML in patients treated for psoriasis. N. Engl. J. Med. 369:1082.
100. Trapp, B. D., J. Peterson, R. M. Ransohoff, R. Rudick, S. Mork, and L. Bo 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-285.
101. ® (natalizumab): PML Incidence in Patients Receiving TYSABRI (December 2014). Medical Information, medinfo@biogenidec.com, http://medinfo.biogenidec.com.
102. Tzartos, J. S., M. A. Friese, M. J. Craner, J. Palace, J. Newcombe, M. M. Esiri, et al. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172:146-155.
103. Weber, F., J. Janovskaja, T. Polak, S. Poser, and P. Rieckmann 1999. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology 52:1069-1071.
104. Weinshenker, B. G. 1996. Epidemiology of multiple sclerosis. Neurol. Clin. 14:291-308.
105. Weinshenker, B. G., B. Bass, G. P. Rice, J. Noseworthy, W. Carriere, J. Baskerville, et al. 1989. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112(Pt 1):133-146.
106. Weinstock-Guttman, B., R. M. Ransohoff, R. P. Kinkel, and R. A. Rudick 1995. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol. 37:7-15.
107. Williams, R., A. S. Rigby, M. Airey, M. Robinson, and H. Ford 1995. Multiple sclerosis: it epidemiological, genetic, and health care impact. J. Epidemiol. Community Health 49:563-569.
108. Wingerchuk, D. M. 2012. Smoking: effects on multiple sclerosis susceptibility and disease progression. Therapeut. Advan. Neurol. Dis. 5:13-22.
109. Wolinsky, J. S. 1995. Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology 45:1245-1247.
110. Wu, C., N. Yosef, T. Thalhamer, C. Zhu, S. Xiao, Y. Kishi, et al. 2013. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496:513-517.
111. Wucherpfennig, K. W., and J. L. Strominger 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705.
112. Yong, V. W. 2004. Immunopathogenesis of multiple sclerosis. Contin. Lifelong Learn. Neurol. 10:11-27.
113. Yong, V. W., S. Chabot, O. Stuve, and G. Williams 1998. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51:682-689.
114. Yousry, T. A., E. O. Major, C. Ryschkewitsch, G. Fahle, S. Fischer, J. Hou, et al. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354:924-933.
115. Zettl, U. K., O. Stuve, and R. Patejdl 2012. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun. Rev. 11:167-173.